Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Factors contributing to retroviral integration have been intractable because past studies have not precisely located genomic sites of proviruses in sufficient numbers for significant analysis. In this study, 903 murine leukemia virus (MLV) and 379 human immunodeficiency virus–1 (HIV-1) integrations in the human genome were mapped. The data showed that MLV preferred integration near the start of transcriptional units (either upstream or downstream) whereas HIV-1 preferred integration anywhere in the transcriptional unit but not upstream of the transcriptional start. Defining different integration site preferences for retroviruses will have important ramifications for gene therapy and may aid in our understanding of the factors directing the integration process.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The well-understood integration preferences of HIV-1 for active transcription units72 and MLV for promoter/enhancer regions73–75 are in large part dictated via specific interactions of the respective IN proteins with chromatin-bound host factors.”
From Structure and function of retroviral integrase (2022) · cites this paper as [73]
In the citing paper
“Multiple studies now indicate that gammaretroviral vectors such as the vectors used in the two SCID-X1 trials preferentially integrate into the 5′ end of genes, near the transcription start sites[47].”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [47]
In the citing paper
“Finally, the preferred sequences of the genome for integration are different from the γ-RVV, with LVV preferentially integrating in genes and introns away for transcriptional start sites preferred by γ-RVV.20”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [20]
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.-P., Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012616 · Cited by 1,058
CpG islands as gene markers in the human genome
Larsen, F., Gundersen, G., Lopez, R., & Prydz, H. (1992) · Genomics · doi:10.1016/0888-7543(92)90024-m · Cited by 922
Pryciak, P. M., & Varmus, H. E. (1992) · Cell · doi:10.1016/0092-8674(92)90289-o · Cited by 273
Introducing RefSeq and LocusLink: curated human genome resources at the NCBI
Pruitt, K. D., Katz, K. S., Sicotte, H., & Maglott, D. R. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01882-x · Cited by 241
Check, E. (2002) · Nature · doi:10.1038/420116a · Cited by 238
Pruss, D., Bushman, F. D., & Wolffe, A. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.5913 · Cited by 236
Transcriptionally active genome regions are preferred targets for retrovirus integration
Scherdin, U., Rhodes, K., & Breindl, M. (1990) · Journal of Virology · doi:10.1128/jvi.64.2.907-912.1990 · Cited by 210
Research works printed but not linked: 2
- National Center for Biotechnology Information Reference Sequence Project (RefSeq) www.ncbi.nlm.nih.gov/RefSeq/.
- The database is available online at www.ncbi.nlm.nih.gov/geo/.
Cited by
Items 601–700 of 1,000
Qi, F., Song, J., Yang, H., Gao, W., Liu, N., Zhang, B., & Lin, S. (2010) · Hepatology · doi:10.1002/hep.23945 · Cited by 29
Mizutani, T., Ishizaka, A., Tomizawa, M., Okazaki, T., Yamamichi, N., Kawana‐Tachikawa, A., Iwamoto, A., & Iba, H. (2009) · Journal of Virology · doi:10.1128/jvi.00742-09 · Cited by 33
Gene Therapy for β-Thalassemia
Malik, P., & Arumugam, P. I. (2005) · Hematology · doi:10.1182/asheducation-2005.1.45 · Cited by 34
Integration of Retroviruses: A Fine Balance between Efficiency and Danger
Fischer, A., & Cavazzana, M. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020010 · Cited by 29
“Data from these pioneering papers were obtained by in vitro infection of mature cells or cell lines with the relevant RV or LV [6,7,8].”
BackgroundThe ups and downs of gene expression and retroviral DNA integration
Engelman, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409587101 · Cited by 31
A primer to gene therapy: Progress, prospects, and problems
Zittersteijn, H. A., Gonçalves, M. A. F. V., & Hoeben, R. C. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12270 · Cited by 30
“These SAEs are facilitated by the propensity of retroviral vectors derived from gamma-retroviruses to integrate with a high preference into the regulatory regions of active genes, in particular into the transcription start sites of these genes.(14,15) To reduce the probability for cellular gene activation by viral pro…”
BackgroundOstracod carnivory through time
Wilkinson, I. P., Wilby, P. R., Williams, P., Siveter, D. J., & Vannier, J. (2007) · Springer eBooks · doi:10.1007/978-3-540-46046-6_4 · Cited by 28
Ng, G. H. B., & Gong, Z. (2011) · Biochimie · doi:10.1016/j.biochi.2011.07.006 · Cited by 28
Genome-Wide Analysis of Alpharetroviral Integration in Human Hematopoietic Stem/Progenitor Cells
Moiani, A., Suerth, J. D., Gandolfi, F., Rizzi, E., Severgnini, M., Bellis, G. D., Schambach, A., & Mavilio, F. (2014) · Genes · doi:10.3390/genes5020415 · Cited by 31
“non-random profiles with a strong tendency to target active regulatory regions for MLV-derived gamma-retroviral vectors [13,14] and transcribed regions for HIV-derived lentiviral vectors [15,16].”
BackgroundTsukahara, T., Agawa, H., Matsumoto, S., Matsuda, M., Ueno, S., Yamashita, Y., Yamada, K., Tanaka, N., Kojima, K., & Takeshita, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.007 · Cited by 31
Moreau, T., Barlogis, V., Bardin, F., Nunès, J. A., Calmels, B., Chabannon, C., & Tonnelle, C. (2008) · Gene Therapy · doi:10.1038/gt.2008.17 · Cited by 28
Hematopoietic stem cell gene therapy with drug resistance genes: an update
Budak-Alpdoǧan, T., Banerjee, D., & Bertino, J. R. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700866 · Cited by 33
Zielske, S. P., Lingas, K. T., Li, Y., & Gerson, S. L. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.02.017 · Cited by 29
“As in vivo gene-mediated drug selection moves into clinical trials, and in light of studies on retroviral integration [1,2], whether cycles of drug selection impact on the distribution of copy number in individual cells should influence the design of these trials.”
BackgroundInfluentialSelf-citationHematopoietic stem cell gene therapy: dead or alive?
Ferguson, C., Larochelle, A., & Dunbar, C. E. (2005) · Trends in biotechnology · doi:10.1016/j.tibtech.2005.09.005 · Cited by 30
Gene therapy of inherited immunodeficiencies
Santilli, G., Thornhill, S. I., Kinnon, C., & Thrasher, A. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.397 · Cited by 31
“While HIV-based vectors integrate within genes [69] , MLV-based vectors preferentially integrate within 5 kb of transcriptional start sites [70] , in particular in actively transcribed genes [71] .”
BackgroundCiuffi, A. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.02.013 · Cited by 27
“Upon the publication of the human genome, pioneering studies using HIV and murine leukaemia virus (MLV, a gammaretrovirus) revealed specific retroviral genomic locations that were preferentially selected for viral integration [10,11].”
BackgroundRittelmeyer, I., Rothe, M., Brugman, M. H., Iken, M., Schambach, A., Manns, M. P., Baum, C., Modlich, U., & Ott, M. (2012) · Hepatology · doi:10.1002/hep.26204 · Cited by 28
Bone Marrow Gene Therapy for HIV/AIDS
Herrera-Carrillo, E., & Berkhout, B. (2015) · Viruses · doi:10.3390/v7072804 · Cited by 32
“LVs tend to integrate within introns of transcribed regions, thereby limiting their potential to cause insertional oncogenesis [121].”
BackgroundVector Integration and Tumorigenesis
Kalle, C. V., Deichmann, A., & Schmidt, M. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2525 · Cited by 31
“Based on the advent and public availability of the almost complete murine and human genome sequence in 2002 and 2003, the characteristics of insertion of viral vectors have been extensively reevaluated (Schroder et al., 2002; Waterston et al., 2002; Wu et al., 2003).”
Knocking down schistosomes – promise for lentiviral transduction in parasites
Hagen, J., Scheerlinck, J. Y., & Gasser, R. B. (2015) · Trends in Parasitology · doi:10.1016/j.pt.2015.03.009 · Cited by 30
Foamy Virus Vector-mediated Gene Correction of a Mouse Model of Wiskott–Aldrich Syndrome
Uchiyama, T., Adriani, M., Jagadeesh, G. J., Paine, A., & Candotti, F. (2012) · Molecular Therapy · doi:10.1038/mt.2011.282 · Cited by 28
Serial number tagging reveals a prominent sequence preference of retrotransposon integration
Chatterjee, A. G., Esnault, C., Guo, Y., Hung, S., McQueen, P. G., & Levin, H. L. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku534 · Cited by 27
Common Viral Integration Sites Identified in Avian Leukosis Virus-Induced B-Cell Lymphomas
Justice, J., Morgan, R. W., & BEEMON, K. L. (2015) · mBio · doi:10.1128/mbio.01863-15 · Cited by 27
“Analyses of other retroviruses such as HIV and murine leukemia virus (MLV) have shown that MLV but not HIV prefers integration near TSSs and CpG islands (41, 42).”
Generation of Induced Pluripotent Stem Cells from Somatic Cells
Sohn, Y.-D., Han, J. W., & Yoon, Y. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-398459-3.00001-0 · Cited by 33
Allu, A. D., Simancas, B., Balazadeh, S., & Munné‐Bosch, S. (2017) · Frontiers in Plant Science · doi:10.3389/fpls.2017.01396 · Cited by 27
“Transcription factors regulate the majority of gene expression changes and thus play a crucial role in regulating the plant response to various stresses including Pi limitation (Wu et al., 2003).”
BackgroundFischer, A., Hacein‐Bey‐Abina, S., Lagresle‐Peyrou, C., Garrigue, A., & Cavazzana, M. (2005) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)33504-6 · Cited by 28
Promise of gene therapy to treat sickle cell disease
Romero, Z. G., DeWitt, M. A., & Walters, M. C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1536119 · Cited by 29
“LV, moreover reduce the risk of insertional onco-genesis, since it tends to integrate in noncoding regions, unlike γ-retrovirus [35].”
BackgroundBeekman, R., Valkhof, M. G., Erkeland, S. J., Taskesen, E., Ročková, V., Peeters, J. K., Valk, P. J. M., Löwenberg, B., & Touw, I. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026537 · Cited by 27
“Because MLVs tend to integrate within 10 kb around the transcriptional start site [15], the nearest genes within 10 kb downstream of these 8 mVIS were determined (Figure 3, Table S1).”
BackgroundRyu, B. Y., Persons, D. A., Evans‐Galea, M. V., Gray, J. T., & Nienhuis, A. W. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.05.003 · Cited by 27
Beard, B. C., Sud, R., Keyser, K. A., Ironside, C. M., Neff, T., Gerull, S., Trobridge, G. D., & Kiem, H. (2009) · Blood · doi:10.1182/blood-2008-09-176412 · Cited by 27
Retrotransposons and regulatory suites
Shapiro, J. A. (2005) · BioEssays · doi:10.1002/bies.20192 · Cited by 29
González‐Murillo, Á., Lozano, M. L., Montini, E., Bueren, J. A., & Güenechea, G. (2008) · Blood · doi:10.1182/blood-2008-03-142661 · Cited by 28
Lucas, M., Seidel, N. E., Porada, C. D., Quigley, J. G., Anderson, S. M., Malech, H. L., Abkowitz, J. L., Zanjani, E. D., & Bodine, D. M. (2005) · Blood · doi:10.1182/blood-2004-11-4491 · Cited by 27
The FACT Complex Promotes Avian Leukosis Virus DNA Integration
Winans, S., Larue, R. C., Abraham, C. M., Shkriabai, N., Skopp, A., Winkler, D., Kvaratskhelia, M., & Beemon, K. L. (2017) · Journal of Virology · doi:10.1128/jvi.00082-17 · Cited by 26
Hotspots of MLV integration in the hematopoietic tumor genome
Tsuruyama, T., Hiratsuka, T., & Yamada, N. (2016) · Oncogene · doi:10.1038/onc.2016.285 · Cited by 31
Two-long terminal repeat (LTR) DNA circles are a substrate for HIV-1 integrase
Richetta, C., Thierry, S., Thierry, E., Lesbats, P., Lapaillerie, D., Munir, S., Subra, F., Leh, H., Deprez, E., Parissi, V., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006755 · Cited by 30
“Integration sites were determined using MfeI restriction enzyme and LM-PCR as previously described (34).”
MethodBustamante, O. Q., Fañanas-Baquero, S., Orman, I., Torres-Ruiz, R., Duchateau, P. N., Poirot, L., Gouble, A., Bueren, J. A., & Segovia, J. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223775 · Cited by 26
“The nucleofection procedure has been shown to be very toxic in some cases[43, 44].”
MethodIdentifying and retargeting transcriptional hot spots in the human genome
Cheng, J. K., Lewis, A. M., Kim, D. S., Dyess, T. J., & Alper, H. S. (2016) · Biotechnology Journal · doi:10.1002/biot.201600015 · Cited by 29
“and preference for CpG islands, regions of high gene density, and regions near transcription start sites and transcription factor binding sites [40, 45-48].”
BackgroundRetroviral-mediated Insertional Mutagenesis in Zebrafish
Amsterdam, A., Varshney, G. K., & Burgess, S. M. (2011) · Methods in cell biology · doi:10.1016/b978-0-12-374814-0.00004-5 · Cited by 26
“1990) and human tissue culture cells (Wu et al. 2003).”
Self-citationEarly stages of HIV replication: how to hijack cellular functions for a successful infection.
Lehmann‐Che, J., & Saïb, A. (2004) · PubMed · Cited by 48
Self-inactivating MLV vectors have a reduced genotoxic profile in human epidermal keratinocytes
Cavazza, A., Cocchiarella, F., Bartholomae, C. C., Schmidt, M., Pincelli, C., Larcher, F., & Mavilio, F. (2013) · Gene Therapy · doi:10.1038/gt.2013.18 · Cited by 27
Motegi, A., & Myung, K. (2006) · Methods · doi:10.1016/j.ymeth.2006.07.025 · Cited by 26
Selden, C., Mellor, N., Rees, M., Laurson-Doube, J., Kirwan, M., Escors, D., Collins, M. K., & Hodgson, H. J. F. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1000 · Cited by 30
“In general, however, the profile of insertion sites of lentivirus appears intrinsically safer (not being clustered around transcription start sites) in contrast to MLV integration sites [25].”
ResultPreparing clinical grade Ag-specific T cells for adoptive immunotherapy trials
DiGiusto, D. L., & Cooper, L. J. N. (2007) · Cytotherapy · doi:10.1080/14653240701650320 · Cited by 27
Sokol, M., Wabl, M. R., Ruiz, I. R., & Pedersen, F. S. (2014) · Retrovirology · doi:10.1186/1742-4690-11-36 · Cited by 27
“While earlier studies suggested that MLVs preferentially target DNase I hypersensitive regions, transcription start sites (TSSs) and CpG islands [16,17], several in vitro studies and studies of cultured primary cells have shown that gamma-retroviral vectors favor integration into nucleosomal DNA [18-24].”
BackgroundNaumann, N., Ravin, S. S. D., Choi, U., Moayeri, M., Whiting‐Theobald, N., Linton, G. F., Ikeda, Y., & Malech, H. L. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303010 · Cited by 29
Structural and sequencing analysis of local target DNA recognition by MLV integrase
Aiyer, S., Rossi, P., Malani, N., Schneider, W. M., Chandar, A., Bushman, F. D., Montelione, G. T., & Roth, M. J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv410 · Cited by 25
“At the chromosomal level, MLV integration preferentially occurs at transcription start sites and CpG islands (2).”
Backgroundde Marco, A., Biancotto, C., Knezevich, A., Maiuri, P., Vardabasso, C., & Marcello, A. (2008) · Retrovirology · doi:10.1186/1742-4690-5-98 · Cited by 28
“Murine leukemia virus (MLV) integrates within highly active promoters at ± 5 kb from the transcription start sites [7,11].”
BackgroundOu, H., Huang, Y., Qu, L., Xu, M., Yan, J., Ren, Z., Huang, S., & Zeng, Y. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06762.x · Cited by 25
Šenigl, F., Plachý, J., & Hejnar, J. (2008) · Journal of Virology · doi:10.1128/jvi.00419-08 · Cited by 25
“MLV also integrates with a high preference for expressed genes, particularly into the transcriptional start sites of genes (51), and such integration might transcriptionally activate adjacent proto-oncogenes, as shown in the SCID-X1 gene therapy trial (17).”
BackgroundInsight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection
Saleh, S. M., Vranckx, L. S., Gijsbers, R., Christ, F., & Debyser, Z. (2017) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30300-9 · Cited by 30
“HIV broadly favours gene-dense chromosomal regions that contain a mixture of favourable clusters of active genes and unfavourable CpG islands [105].”
BackgroundGiannoudis, P. V., Tzioupis, C. C., & Tsirids, E. (2006) · Injury · doi:10.1016/j.injury.2006.02.038 · Cited by 26
Transposons for cancer gene discovery: Sleeping Beauty and beyond
Collier, L. S., & Largaespada, D. A. (2007) · Genome biology · doi:10.1186/gb-2007-8-s1-s15 · Cited by 29
“entire genome equally because they have a strong preference for landing near the promoter region of actively transcribed genes [13,14].”
BackgroundTurunen, T. A. K., Kurkipuro, J., Heikura, T., Vuorio, T., Hytönen, E., Izsvák, Z., & Ylä‐Herttuala, S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.221 · Cited by 24
Murphy, L. A., Marians, R. C., Miller, K. R., Brenton, M. D., Mallo, R., Kohler, M. E., Fry, T. J., & Winters, A. C. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.09.004 · Cited by 24
Gene therapies for mucopolysaccharidoses
Rossi, A., & Brunetti‐Pierri, N. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12626 · Cited by 25
“15 19 Integration of gamma-retroviral vectors occurred near the 5 0 ends of transcription units 20 and the strong enhancer activity of their viral long terminal repeat (LTR) elements induced the activation of nearby oncogenes (e.g., LMO2 , CCND2 , and MECOM ) that resulted in clonal expansion of…”
BackgroundSleeping Beauty–baculovirus hybrid vectors for long‐term gene expression in the eye
Turunen, T. A. K., Laakkonen, J. P., Alasaarela, L., Airenne, K. J., & Ylä‐Herttuala, S. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2756 · Cited by 24
Miyasaka, T., Oguma, K., & Sentsui, H. (2014) · Archives of Virology · doi:10.1007/s00705-014-2224-y · Cited by 24
“Likewise, murine leukemia viruses (MLVs) favor integration near transcription start sites and CpG islands [31, 33].”
BackgroundRusso, E. M. D. S., Picanço‐Castro, V., Alves, D. C. C., Fernandes, A. C., Almeida-Porada, G. D., Tonn, T., & Covas, D. T. (2010) · Biotechnology Letters · doi:10.1007/s10529-010-0387-5 · Cited by 26
“Ligation-mediated polymerase chain reaction (LMPCR) was performed as previously described (Wu et al. 2003).”
MethodRecombinant Glycoprotein Production in Human Cell Lines
Swiech, K., de Freitas, M. C. C., Covas, D. T., & Picanço‐Castro, V. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-2205-5_12 · Cited by 24
Bii, V. M., Collins, C. P., Hocum, J. D., & Trobridge, G. D. (2018) · Oncotarget · doi:10.18632/oncotarget.24503 · Cited by 24
“γRV vectors have a high propensity to integrate near expressed gene regions, transcription start sites, and gene promoters [17].”
BackgroundDooner, H. K., Wang, Q., Huang, J. T., Li, Y., He, L., Xiong, W., & Du, C. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903809116 · Cited by 26
Self-citationChromatin tethering and retroviral integration: Recent discoveries and parallels with DNA viruses
Meehan, A. M., & Poeschla, E. M. (2009) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.10.001 · Cited by 27
“The new findings from the human trials, along with evidence that retroviruses display specific integration patterns, with MLV preferentially integrating in and around promoters[26, 27], have re-focused the field.”
BackgroundAdvances in tumour immunotherapy
King, J. P., Waxman, J. H., & Stauss, H. J. (2008) · QJM · doi:10.1093/qjmed/hcn050 · Cited by 33
“A number of strategies are also being investigated to reduce the risk of insertional mutagenesis, including the use of single rather than multiple vectors, self inactivating vectors with deleted U3 long terminal repeat regions, the addition of suicide genes into retroviral vectors to allow the selective elimination of…”
BackgroundVranckx, L. S., Demeulemeester, J., Debyser, Z., & Gijsbers, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164167 · Cited by 24
Gene Therapy Through Autologous Transplantation of Gene-Modified Hematopoietic Stem Cells
Kohn, D. B., Pai, S., & Sadelain, M. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.09.021 · Cited by 26
Bressan, F. F., Miranda, M. D. S., Perecin, F., De, T. H. C., Pereira, F. T. V., Russo, E. M. D. S., Alves, D. C. C., Strauss, B. E., Bajgelman, M. C., Krieger, J. E., et al. (2011) · Cellular Reprogramming · doi:10.1089/cell.2010.0022 · Cited by 24
“For identification of the integration site of the transgene in the fibroblast line used for the recloning, genomic DNA was extracted as described above and processed and analyzed similar to as described by Wu et al. (2003).”
Integration Site and Clonal Expansion in Human Chronic Retroviral Infection and Gene Therapy
Niederer, H. A., & Bangham, C. R. M. (2014) · Viruses · doi:10.3390/v6114140 · Cited by 24
“MLV preferentially integrates near transcriptional start sites (TSS) and gene regulatory elements such as promoters and enhancers [49–52].”
BackgroundÜstek, D., Sırma, S., Gümüş, E., Arıkan, M., Çakiris, A., Abacı, N., Mathew, J., Emrence, Z., Azaklı, H., Coşan, F., et al. (2012) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2012.05.001 · Cited by 25
Tschorn, N., Berg, K., & Stitz, J. (2020) · Biotechnology Letters · doi:10.1007/s10529-020-02889-y · Cited by 23
Uchida, N., Evans, M., Hsieh, M. M., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Sellers, S. E., Dunbar, C. E., Donahue, R. E., & Tisdale, J. F. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.49 · Cited by 24
Westwood, J. A., Murray, W. K., Trivett, M., Shin, A., Neeson, P. J., MacGregor, D. P., Haynes, N. M., Trapani, J. A., Mayura-Guru, P., Fox, S. B., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.47 · Cited by 25
Moalic, Y., Félix, H., Takeuchi, Y., Jestin, A., & Blanchard, Y. (2008) · Journal of Virology · doi:10.1128/jvi.00856-08 · Cited by 24
“Affinity for the CpG area and TSS was clearly demonstrated in previous studies (23, 39).”
BackgroundMethodResultInfluentialLoewen, N. A., & Poeschla, E. M. (2005) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_007 · Cited by 31
Gene therapy for immunodeficiency diseases
Fischer, A., Hacein‐Bey‐Abina, S., & Cavazzana, M. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.07.003 · Cited by 27
A realistic chance for gene therapy in the near future
Worgall, S. (2004) · Pediatric Nephrology · doi:10.1007/s00467-004-1680-0 · Cited by 30
“risk [47, 48, 49].”
Innate and Adaptive Factors Regulating Human Immunodeficiency Virus Type 1 Genomic Activation
Shah, S., Nonnemacher, M. R., Pirrone, V., & Wigdahl, B. L. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9207-x · Cited by 25
“This has been shown to be true for both resting and activated CD4+ T cells (Barr et al. 2005; Berry et al. 2006; Bushman et al. 2005; Lewinski et al. 2006; Marshall et al. 2007; Mitchell et al. 2004; Wang et al. 2007; Wu et al. 2003).”
Hunter, M. J., Zhao, H., Tuschong, L. M., Bauer, T. R., Burkholder, T. H., Persons, D. A., & Hickstein, D. D. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.130 · Cited by 27
“Third-generation human immunodeficiency virus (HIV)-derived lentiviral (LV) vectors possess several distinct advantages over RV vectors: LV vectors transduce hematopoietic stem cells at a higher efficiency than RV vectors since LV vectors do not require mitosis for nuclear entry; LV vectors have a more favorable integ…”
Bauer, T. R., Olson, E. M., Huo, Y., Tuschong, L. M., Allen, J. M., Li, Y., Burkholder, T. H., & Russell, D. W. (2011) · Gene Therapy · doi:10.1038/gt.2010.169 · Cited by 22
“These vectors preferentially integrate in actively transcribed genes and near transcription start sites 8 , making it likely that the large populations of transduced cells transplanted during HSC gene therapy contain clones with vector proviruses near proto-oncogenes.”
Self-citationTheSleeping Beautytransposon system for clinical applications
Swierczek, M., Izsvák, Z., & Ivics, Z. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.642358 · Cited by 23
“This is in contrast to retroviral vectors that have profound preferences for insertion into and near transcription units [54-56] and whose clinical-grade production is more demanding, costly and might be associated with a risk of contamination with replication-competent viruses (Table 1).”
ResultSellers, S. E., Gomes, T. J., Larochelle, A., Lopez, R., Adler, R. L., Krouse, A. E., Donahue, R. E., Childs, R. W., & Dunbar, C. E. (2010) · Molecular Therapy · doi:10.1038/mt.2010.117 · Cited by 22
Cellular Superspreaders: An Epidemiological Perspective on HIV Infection inside the Body
Talbert‐Slagle, K., Atkins, K. E., Yan, K., Khurana, E., Gerstein, M., Bradley, E. H., Berg, D. N., Galvani, A. P., & Townsend, J. P. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004092 · Cited by 23
“HIV viral DNA preferentially integrates at sites of active cellular gene expression although not at any specific site or in any specific gene [47] [48] [49] .”
BackgroundNowrouzi, A., Cheung, W., Li, T., Zhang, X., Arens, A., Paruzynski, A., Waddington, S. N., Osejindu, E., Reja, S., Kalle, C. V., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.224 · Cited by 24
Smith, B. A., Shelton, D. N., Kieffer, C., Milash, B. A., Usary, J., Perou, C. M., Bernard, P. S., & Welm, B. E. (2012) · Genes & Cancer · doi:10.1177/1947601913475359 · Cited by 22
“Ligation-mediated PCR was performed as previously described.(53,54) In brief, 100 ng of DNA, harvested from tumors, was completely fragmented by overnight digestion with the Mse1 restriction enzyme.”
MethodA Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies
Zittersteijn, H. A., Harteveld, C. L., Klaver-Flores, S., Lankester, A. C., Hoeben, R. C., Staal, F. J. T., & Gonçalves, M. A. F. V. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.617780 · Cited by 24
A Plasmid-Expressed CRISPR/Cas9 System Suppresses Replication of HSV Type I in a Vero Cell Culture
Karpov, D. S., Карпов, В. Л., Рафаиловна, К. Р., Demidova, N. A., & Aa, K. (2019) · Molecular Biology · doi:10.1134/s0026893319010059 · Cited by 21
Cancer gene discovery in mouse and man
Mattison, J., van der Weyden, L., Hubbard, T., & Adams, D. J. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.03.001 · Cited by 30
Pelascini, L. P. L., Maggio, I., Liu, J., Holkers, M., Cathomen, T., & Gonçalves, M. A. F. V. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.107 · Cited by 23
“Another of their features concerns a semirandom chromosomal DNA integration profile, which results in the permanent genetic modification of target cells (Schro¨der et al. , 2002; Wu et al. , 2003).”
Retrotransposon Target Site Selection by Imitation of a Cellular Protein
Brady, T., Fuerst, P. G., Dick, R. A., Schmidt, C. L., & Voytas, D. F. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01502-07 · Cited by 27
Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Kremer, E. J. (2005) · Current Genomics · doi:10.2174/1389202053202111 · Cited by 24
“This lack of sensitivity is certainly due to the specific physiological roles and therefore expression of a subset of genes in isolated, distinct and small nuclei within the CNS.”
BackgroundŠenigl, F., Auxt, M., & Hejnar, J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks197 · Cited by 23
“In striking contrast, integrations of gamma-retroviruses and spuma-retroviruses are over-represented around TSSs and CpG islands (5,9,10), which might be the cause of documented genotoxicity and leukemia induction by a murine leukemia virus (MLV)derived vector in a gene therapy trial (11).”
BackgroundGene therapy for β-thalassaemia: the continuing challenge
Yannaki, E., Emery, D. W., & Stamatoyannopoulos, G. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001626 · Cited by 24
Update on clinical gene therapy in childhood
Qasim, W., Gaspar, H. B., & Thrasher, A. J. (2007) · Archives of Disease in Childhood · doi:10.1136/adc.2006.108787 · Cited by 21
Targeting Integration of the Saccharomyces Ty5 Retrotransposon
Brady, T., Schmidt, C. L., & Voytas, D. F. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-232-8_11 · Cited by 22
Drew, H. R., Lockett, L. J., & Both, G. W. (2007) · Journal of General Virology · doi:10.1099/vir.0.82880-0 · Cited by 25
“We therefore adapted strategies used by others (Recchia et al., 2004; Wu et al., 2003; Narezkina et al., 2004; Schroder et al., 2002) to monitor integration events in unselected infected-cell genomes.”
BackgroundMethodT-cell receptor gene therapy for cancer: the progress to date and future objectives
Thomas, S., Hart, D. P., Xue, S., Cesco-Gaspere, M., & Stauss, H. J. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.8.1207 · Cited by 21
“Although both retroviruses and lentiviruses insert near active genes, retroviruses insert evenly upstream and downstream of the transcriptional start site, whereas lentiviruses preferentially integrate downstream of the transcriptional start site [63] .”
BackgroundDo Alu repeats drive the evolution of the primate transcriptome?
Urrutia, A. O., Ocaña, L. B., & Hurst, L. D. (2008) · Genome biology · doi:10.1186/gb-2008-9-2-r25 · Cited by 24
“Several retroelements exhibit an open chromatin 5' insertion flanking region bias [56], which could provide a neutral hypothesis to, in part, explain the observed Alu pattern.”
BackgroundGene therapy progress and prospects: gene therapy for severe combined immunodeficiency
Gaspar, H. B., Howe, S. J., & Thrasher, A. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302150 · Cited by 23
Nonhuman primate embryonic stem cells as a preclinical model for hematopoietic and vascular repair
Hematti, P., Obrtlíková, P., & Kaufman, D. S. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2005.06.008 · Cited by 23
“Similar nonrandom integration of retroviral vectors into the genome of the host cells has been shown in cell lines in vitro [30,31] and very importantly in nonhuman primates in vivo [32].”
BackgroundHuman Immunodeficiency Virus (HIV)-1 Integration Sites in Viral Latency
Rezaei, S. D., & Cameron, P. U. (2015) · Current HIV/AIDS Reports · doi:10.1007/s11904-014-0241-9 · Cited by 25
Metadata
- Authors
- Wu, X., Li, Y., Crise, B., & Burgess, S. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Burgess, Shawn M.
- Venue
- Science
- Published
- 2003-06-13
- Volume
- 300
- Issue
- 5626
- Pages
- 1749-1751
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1637867377
- Cited by
- 1,305
- References
- 18
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 25 · 2020: 27 · 2019: 33 · 2018: 24 · 2017: 39 · 2016: 43 · 2015: 49 · 2014: 65 · 2013: 51 · 2012: 83
- FWCI
- 57.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01co12400-79-0-22)
- National Cancer Institute (N01CO12400)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Chromosomal and Genetic Variations
- Keywords
- retroviral integration, transcription start sites, murine leukemia virus, HIV-1, human genome, gene therapy
- MeSH terms
- Child, Genetic Vectors, HeLa Cells, Humans, Leukemia, Leukemia Virus, Murine, Promoter Regions, Genetic, Transcription, Genetic, Tumor Cells, Cultured, Genetic Therapy, HIV-1, Gene Expression, Genome, Human, Virus Integration, CpG Islands, Oligonucleotide Array Sequence Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.